REG - Hutchmed China Ltd - HUTCHMED to Announce 2021 Final Results

HUTCHMED (China)Announcement

07/02/2022 08:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220207:nRSG7818Aa&default-theme=true

RNS Number : 7818A  Hutchmed (China) Limited  07 February 2022

HUTCHMED to Announce 2021 Final Results

 

Hong Kong, Shanghai & Florham Park, NJ - Monday, February 7, 2022:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) ")
(Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year
ended December 31, 2021 on Thursday, March 3, 2022 at 7:00 am Eastern Standard
Time (EST) / 12:00 noon Greenwich Mean Time (GMT) / 8:00 pm Hong Kong Time
(HKT).

 

Analysts and investors are invited to join a conference call and audio webcast
presentation with Q&A, conducted by HUTCHMED management.

 

The conference call and audio webcast will take place at 8:00 am EST / 1:00 pm
GMT / 9:00 pm HKT on Thursday, March 3, 2022 and will be webcast live via the
company website at www.hutch-med.com/event/ (https://www.hutch-med.com/event/)
. The presentation will be available for downloading before the conference
call begins. Details of the conference call dial-in will be provided in the
financial results announcement and on the company website.  A replay will
also be available on the website shortly after the event.

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. It has more than 4,600
personnel across all its companies, at the center of which is a team of about
1,500 in oncology/immunology. Since inception it has advanced 12 cancer drug
candidates from in-house discovery into clinical studies around the world,
with its first three oncology drugs now approved and marketed in China. For
more information, please visit: www.hutch‑med.com
(https://www.hutch-med.com/) or follow us on LinkedIn
(https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries
 Mark Lee, Senior Vice President    +852 2121 8200
 Annie Cheng, Vice President        +1 (973) 567 3786

 Media Enquiries
 Americas - Brad Miles,             +1 (917) 570 7340 (Mobile)

Solebury Trout                    bmiles@troutgroup.com (mailto:bmiles@troutgroup.com)
 Europe - Ben Atwell / Alex Shaw,   +44 20 3727 1030 / +44 7771 913 902 (Mobile) /

FTI Consulting                    +44 7779 545 055 (Mobile)
                                    HUTCHMED@fticonsulting.com (mailto:HUTCHMED@fticonsulting.com)
 Asia - Zhou Yi,                    +852 9783 6894 (Mobile)

Brunswick                         HUTCHMED@brunswickgroup.com (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley,  +44 (20) 7886 2500

Panmure Gordon (UK) Limited

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORFZGGZFDFGZZM